Financial Ratios LB Pharmaceuticals Inc

Equities

LBRX

US50180M1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
25.67 ^USD	+2.93%		+7.95%	+15.32%

Mar. 10	LB Pharmaceuticals Inc Approves the Promotion of Gad Soffer, the Chief Business Officer, to the Position of Chief Operating and Business Officer, Effective March 4, 2026	CI
Mar. 09	Certain Class A Common Stock Warrants of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI

f22c9d88303ee852d1d.soxLVkQh_Latd1kMTC2s3kLxpB6duz-mcQIxXt_IdHM.yLgDbxBqxYXhExVhJ3zOuAbG5k_OwwaLPHdfMqu8GwDezgknAW6N-ssdNg

Published financial data: LB PHARMACEUTICALS INC

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2022	2023	2024
Selling General & Admin Expenses, Total	1.46M	3.53M	13.66M
R&D Expenses	1.35M	7.84M	51.17M
Other Operating Expenses, Total	2.81M	11.38M	64.83M
Operating Income	-2.81M	-11.38M	-64.83M
Interest Expense, Total	-2.15M	-4.82M	-
Interest And Investment Income	73K	811K	1.72M
Net Interest Expenses	-2.08M	-4.01M	1.72M
Other Non Operating Income (Expenses)	-9.46M	16.22M	-947K
EBT, Excl. Unusual Items	-14.35M	833K	-64.06M
Gain (Loss) On Sale Of Investments	2K	328K	955K
Other Unusual Items	-	-7.44M	-
EBT, Incl. Unusual Items	-14.35M	-6.27M	-63.1M
Income Tax Expense	1K	1K	1K
Earnings From Continuing Operations	-14.35M	-6.28M	-63.1M
Net Income to Company	-14.35M	-6.28M	-63.1M
Net Income - (IS)	-14.35M	-6.28M	-63.1M
Net Income to Common Incl Extra Items	-14.35M	-6.28M	-63.1M
Net Income to Common Excl. Extra Items	-14.35M	-6.28M	-63.1M
Per Share Items
Net EPS - Basic	-62.09	-25.14	-250.61
Basic EPS - Continuing Operations	-62.09	-25.14	-250.61
Basic Weighted Average Shares Outstanding	231K	250K	252K
Net EPS - Diluted	-62.09	-25.14	-250.61
Diluted EPS - Continuing Operations	-62.09	-25.14	-250.61
Diluted Weighted Average Shares Outstanding	231K	250K	252K
Normalized Basic EPS	-38.81	2.09	-159
Normalized Diluted EPS	-38.81	2.09	-159
Supplemental Items
EBITDA	-2.81M	-11.37M	-64.74M
EBITA	-2.81M	-11.38M	-64.83M
EBIT	-2.81M	-11.38M	-64.83M
EBITDAR	-2.76M	-11.3M	-64.31M
Effective Tax Rate - (Ratio)	-0.01	-0.02	-0
Current Domestic Taxes	1K	1K	1K
Total Current Taxes	1K	1K	1K
Normalized Net Income	-8.97M	521K	-40.04M
Interest on Long-Term Debt	2.15M	4.82M	-
Supplemental Operating Expense Items
General and Administrative Expenses	1.41M	3.46M	13.66M
Research And Development Expense From Footnotes	1.35M	7.84M	51.17M
Net Rental Expense, Total	50K	70K	427K
Stock-Based Comp., R&D Exp. (Total)	-	-	396K
Stock-Based Comp., G&A Exp. (Total)	-	-	2.69M
Stock-Based Comp., Other (Total)	431K	295K	74K
Total Stock-Based Compensation	431K	295K	3.16M

Fiscal Period: December	2022	2023	2024
Assets
Cash And Equivalents	21.4M	14.98M	22.98M
Short Term Investments	-	28.31M	5.02M
Total Cash And Short Term Investments	21.4M	43.29M	28M
Prepaid Expenses	76K	2.33M	880K
Other Current Assets, Total	9K	9K	-
Total Current Assets	21.49M	45.63M	28.88M
Gross Property Plant And Equipment	10K	34K	4.26M
Accumulated Depreciation	-7K	-11K	-101K
Net Property Plant And Equipment	3K	23K	4.16M
Other Long-Term Assets, Total	-	-	498K
Total Assets	21.49M	45.66M	33.53M
Liabilities
Accounts Payable, Total	156K	1.39M	2.32M
Accrued Expenses, Total	313K	1.22M	5.3M
Current Portion of Leases	-	-	487K
Total Current Liabilities	469K	2.61M	8.11M
Long-Term Debt	24.15M	-	-
Long-Term Leases	-	-	3.22M
Other Non Current Liabilities	18.49M	1.56M	2.5M
Total Liabilities	43.11M	4.16M	13.83M
Preferred Stock Convertible	7.19M	75.97M	114M
Total Preferred Equity	7.19M	75.97M	114M
Common Stock, Total	1K	1K	1K
Additional Paid In Capital	6.13M	6.47M	9.66M
Retained Earnings	-34.95M	-41.22M	-104M
Comprehensive Income and Other	-	274K	111K
Total Common Equity	-28.81M	-34.47M	-94.55M
Total Equity	-21.62M	41.49M	19.7M
Total Liabilities And Equity	21.49M	45.66M	33.53M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	231K	250K	252K
ECS Total Common Shares Outstanding	231K	250K	252K
Book Value / Share	-124.68	-138.11	-375.53
Tangible Book Value	-28.81M	-34.47M	-94.55M
Tangible Book Value Per Share	-124.68	-138.11	-375.53
Total Debt	24.15M	0	3.7M
Net Debt	2.74M	-43.29M	-24.3M
Debt Equivalent Oper. Leases	400K	560K	3.42M
Account Code - Inventory Valuation	-	3	3
Machinery, Total	10K	34K	469K

Fiscal Period: December	2022	2023	2024
Net Income	-14.35M	-6.28M	-63.1M
Depreciation & Amortization - CF	2K	4K	91K
Depreciation & Amortization, Total	2K	4K	91K
Amortization of Deferred Charges, Total - (CF)	1.64M	3.88M	3.22M
(Gain) Loss on Sale of Investments - (CF)	-2K	-328K	-989K
Stock-Based Compensation (CF)	431K	295K	3.16M
Other Operating Activities, Total	9.46M	-8.79M	1.26M
Change In Accounts Payable	131K	1.1M	5.02M
Change in Other Net Operating Assets	-45K	-2.26M	-1.7M
Cash from Operations	-2.73M	-12.37M	-53.05M
Capital Expenditure	-	-25K	-769K
Investment in Marketable and Equity Securities, Total	123K	-27.71M	24M
Cash from Investing	123K	-27.74M	23.23M
Long-Term Debt Issued, Total	25M	725K	-
Total Debt Issued	25M	725K	-
Issuance of Common Stock	-	1K	23K
Issuance of Preferred Stock	903K	35M	40M
Other Financing Activities, Total	-2.95M	-2.05M	-1.71M
Cash from Financing	22.96M	33.68M	38.32M
Net Change in Cash	20.36M	-6.42M	8.5M
Supplemental Items
Cash Interest Paid	-	1.98M	-
Cash Income Tax Paid (Refund)	1K	1K	1K
Levered Free Cash Flow	-	-6.09M	-28.34M
Unlevered Free Cash Flow	-	-6.96M	-28.34M
Change In Net Working Capital	-	121K	-6.48M
Net Debt Issued / Repaid	25M	725K	-

Fiscal Period: December	2022	2023	2024
Profitability
Return on Assets	-	-21.18	-102.33
Return on Total Capital	-	-32.3	-124.86
Return On Equity %	-	-63.14	-206.22
Return on Common Equity	-	19.83	97.81
Short Term Liquidity
Current Ratio	45.82	17.51	3.56
Quick Ratio	45.64	16.61	3.45
Operating Cash Flow to Current Liabilities	-5.82	-4.75	-6.54
Long Term Solvency
Total Debt/Equity	-111.7	-	18.79
Total Debt / Total Capital	954.47	-	15.82
LT Debt/Equity	-111.7	-	16.32
Long-Term Debt / Total Capital	954.47	-	13.74
Total Liabilities / Total Assets	200.59	9.12	41.24
EBIT / Interest Expense	-1.31	-2.36	-
EBITDA / Interest Expense	-1.3	-2.36	-
(EBITDA - Capex) / Interest Expense	-1.3	-2.36	-
Total Debt / EBITDA	-8.6	-	-0.06
Net Debt / EBITDA	-0.98	3.81	0.38
Total Debt / (EBITDA - Capex)	-8.6	-	-0.06
Net Debt / (EBITDA - Capex)	-0.98	3.8	0.37
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	-	305.13	469.28
EBITA, 1 Yr. Growth %	-	304.98	469.88
EBIT, 1 Yr. Growth %	-	304.98	469.88
Earnings From Cont. Operations, 1 Yr. Growth %	-	-56.27	905.61
Net Income, 1 Yr. Growth %	-	-56.27	905.61
Normalized Net Income, 1 Yr. Growth %	-	-105.81	-7.79K
Diluted EPS Before Extra, 1 Yr. Growth %	-	-59.51	896.89
Net Property, Plant and Equip., 1 Yr. Growth %	-	666.67	17.97K
Total Assets, 1 Yr. Growth %	-	112.44	-26.55
Tangible Book Value, 1 Yr. Growth %	-	19.65	174.28
Common Equity, 1 Yr. Growth %	-	19.65	174.28
Cash From Operations, 1 Yr. Growth %	-	353.37	338.66
Capital Expenditures, 1 Yr. Growth %	-	-	2.98K
Levered Free Cash Flow, 1 Yr. Growth %	-	-	365.34
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	307.33
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	-	380.24
EBITA, 2 Yr. CAGR %	-	-	380.41
EBIT, 2 Yr. CAGR %	-	-	380.41
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	109.71
Net Income, 2 Yr. CAGR %	-	-	109.71
Normalized Net Income, 2 Yr. CAGR %	-	-	111.29
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	100.9
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	3.62K
Total Assets, 2 Yr. CAGR %	-	-	24.91
Tangible Book Value, 2 Yr. CAGR %	-	-	81.16
Common Equity, 2 Yr. CAGR %	-	-	81.16
Cash From Operations, 2 Yr. CAGR %	-	-	340.99